[Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction].
The early intravenous administration of thrombolytic agents in the acute phase of myocardial infarction induces reperfusion of the artery responsible for the necrosis, thereby limiting the size of the infarct and preserving the left ventricular systolic function with consequent reduction of short- or long-term mortality. With the exception of urokinase, these effects have been demonstrated with all thrombolytic agents used so far, including streptokinase, plasminogen tissue activator and anistreplase. Owing to its special pharmacokinetic properties, the latest thrombolytic agent, formerly known as APSAC (anisoylated plasminogen streptokinase activator complex), provides a high arterial reperfusion rate with a low percentage of reocclusion. As a result, the mean size of the infarct is reduced by 31 per cent (36% in the case of anterior infarct), and the left ventricular systolic function is highly significantly preserved.
Bassand
J P
JP
Service de cardiologie, hôpital universitaire Saint-Jacques, Besançon.
Cassagnes
J
J
Machecourt
J
J
Anguenot
T
T
Lusson
J R
JR
Borel
E
E
Schiele
F
F
Wolf
J F
JF
Vachet
D
D
D016255:Anistreplase; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects*; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D015425:Myocardial Reperfusion / Q000379:methods*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D010958:Plasminogen / Q000494:pharmacology*; D011877:Radionuclide Imaging; D013300:Streptokinase / Q000494:pharmacology*; D013599:Systole / Q000187:drug effects*; D013794:Thallium Radioisotopes; D010959:Tissue Plasminogen Activator / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D005343:Fibrinolytic Agents; D013794:Thallium Radioisotopes; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Effet des thrombolytiques sur la taille de la nécrose et la fonction systolique ventriculaire gauche dans l'infarctus du myocarde.